This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
References
1) Ricottini E et al. Insulin-requiring versus non-insulin requiring diabetes and
thromboembolic risk in patients with atrial fibrillation: a PREFER in AF Registry
substudy. [Abstract accepted for presentation at ESC Congress 2016].
2) Schnabel RB et al. Gender differences in clinical Presentation and predictors of
one-year outcomes in atrial fibrillation. [Abstract accepted for presentation at ESC
Congress 2016].
3) Kirchhof P, et al. Management of atrial fibrillation in seven European countries after
the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of
the PREvention oF thromboembolic events - European Registry in Atrial Fibrillation
(PREFER in AF). Europace 2013. doi: 10.1093/europace/eut263.
4) PREFER in AF Prolongation Registry. European Multinational Prolongation Registry on
Prevention of Thromboembolic Events in Atrial Fibrillation. DSE-EAF-01-13. Data on
file.
5) National Heart, Lung and Blood Institute - What is Atrial Fibrillation. Available
at: http://www.nhlbi.nih.gov/health/dci/Dise.... Last
accessed: July 2016.
6) Iqbal MB, et al. Recent developments in atrial fibrillation. BMJ. 2005;330(7485)
:238-43.
7) Camm, A. et al. ESC Guidelines for the management of atrial fibrillation: the Task
Force for the Management of Atrial Fibrillation. Eur Heart J. 2010;31(19):2369-2429.
8) Ball J, et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the
21st century. Int J Card. 2013;167:1807-1824.
EDX/16/0183
August 2016
Contact
Lydia Worms (Europe)
Daiichi Sankyo Europe GmbH
Edoxaban Communications & Product PR Europe
+49-(89)-7808751
